Non–small cell lung cancer (NSCLC) remains a significant global health burden and is a leading cause of cancer-related death. The correct staging of patients with NSCLC is a key step in selecting an adequate treatment regimen, and combined positron emission tomography–computed tomography (PET-CT) with fluorine 18–labeled fluorodeoxyglucose (FDG) is increasingly used for staging and treatment monitoring of patients with NSCLC. The principal strengths of PET-CT with FDG in staging NSCLC include the assessment of intrathoracic lymph nodes and the detection of unanticipated stage IV disease. However, data on the effects of PET-CT with FDG on cancer-related mortality in NSCLC remain sparse.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Walter MA. The Role of Positron Emission Tomography–Computed Tomography in the Workup of Non–Small Cell Lung Cancer. JAMA Netw Open. 2019;2(11):e1915873. doi:10.1001/jamanetworkopen.2019.15873
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: